Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
Real-time Estimate Cboe BZX  -  01:15 2022-09-27 pm EDT
18.36 USD   +4.44%
06:47aStifel Adjusts Price Target on Deciphera Pharmaceuticals to $18 From $11, Reiterates Hold Rating
MT
09/12Piper Sandler Raises Deciphera Pharmaceuticals Price Target to $18 From $13, Maintains Neutral Rating
MT
09/12SVB Securities Adjusts Deciphera Pharmaceuticals' Price Target to $25 from $21, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 3 1773 2495711 175--
Enterprise Value (EV)1 2 5972 6974849859721 175
P/E ratio -13,9x-11,9x-1,89x-6,94x-7,86x-10,1x
Yield ------
Capitalization / Revenue 127x77,2x5,94x9,06x7,54x6,09x
EV / Revenue 104x64,1x5,04x7,59x6,24x6,09x
EV / EBITDA -13,0x-10,0x-1,63x-5,71x-7,08x-
Price to Book 5,88x6,05x1,88x3,78x5,64x-
Nbr of stocks (in thousands) 51 04456 93358 48166 822--
Reference price (USD) 62,257,19,7717,617,617,6
Announcement Date 03/09/202002/09/202102/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 25,042,196,1130156193
EBITDA1 -200-269-297-172-137-
Operating profit (EBIT)1 -201-271-300-181-168-145
Operating Margin -803%-644%-312%-139%-108%-75,1%
Pre-Tax Profit (EBT)1 -192-266-300-180-166-150
Net income1 -192-266-300-178-168-139
Net margin -769%-633%-312%-138%-108%-71,8%
EPS2 -4,48-4,78-5,16-2,53-2,24-1,75
Dividend per Share ------
Announcement Date 03/09/202002/09/202102/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 24,229,232,533,035,034,1
EBITDA1 -87,6-46,1-43,0-42,0-42,0-
Operating profit (EBIT)1 -88,4-46,9-43,8-44,2-45,5-44,8
Operating Margin -365%-160%-135%-134%-130%-132%
Pre-Tax Profit (EBT)1 -88,4-46,9-43,1-44,2-46,1-44,2
Net income1 -88,4-46,9-43,1-43,7-44,6-44,8
Net margin -365%-160%-133%-133%-128%-131%
EPS2 -1,51-0,80-0,60-0,58-0,59-0,59
Dividend per Share ------
Announcement Date 02/08/202205/04/202208/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 58055287,1190203-
Leverage (Debt / EBITDA) 2,90x2,05x0,29x1,10x1,48x-
Free Cash Flow1 -154-245-243-143-132-121
ROE (Net Profit / Equities) -46,5%-48,9%-70,7%-53,6%-45,8%-
Shareholders' equity1 413545424333366-
ROA (Net Profit / Asset) -41,0%-42,1%-56,0%-39,8%-34,9%-
Assets1 469632536448480-
Book Value Per Share2 10,69,445,204,653,11-
Cash Flow per Share -3,48-----
Capex1 4,945,321,971,231,532,31
Capex / Sales 19,7%12,6%2,05%0,95%0,98%1,20%
Announcement Date 03/09/202002/09/202102/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 1 174 732 271
Net sales (USD) 96 148 000
Number of employees 280
Sales / Employee (USD) 343 386
Free-Float 72,4%
Free-Float capitalization (USD) 850 071 775
Avg. Exchange 20 sessions (USD) 18 790 837
Average Daily Capital Traded 1,60%
EPS & Dividend